Alpha 1-Antitrypsin Deficiency: all 93 studies

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• Preparation of IPSC for Cell Gene Editing for the Treatment of AATDEnrolling by invitationNCT06892236Not applicable
• Permian Health Women's Lung Health StudyNot yet recruitingNCT06029543
• Czech AATD RegistryRecruitingNCT05178277
• Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung DiseaseRecruitingNCT03455686Not applicable
• Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)TerminatedNCT04547140Phase 2Results posted
• Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ GenotypeCompletedNCT04474197Phase 2Results posted
• Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ GenotypeTerminatedNCT04167345Phase 2Results posted
• Long-Term Follow-up Study of ADVM-043CompletedNCT03804021Results posted
• A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHDCompletedNCT03459040Phase 2Results posted
• Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin DeficiencyCompletedNCT03008915Phase 2Results posted
• Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic PancreatitisCompletedNCT02947087Phase 1/2Results posted
• Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)CompletedNCT02870348Phase 1/2Results posted
• Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin DeficiencyCompletedNCT02870309Phase 1/2Results posted
• Alpha-1 Carrier Genomics StudyCompletedNCT02810327Results posted
• Stage 1 Study of ARALAST NP and GLASSIA in A1PI DeficiencyTerminatedNCT02722304Phase 3Results posted
• GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage StudyCompletedNCT02525861Phase 3Results posted
• A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin DeficiencyCompletedNCT02282527Phase 2/3Results posted
• Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) DeficiencyCompletedNCT02168686Phase 1/2Results posted
• Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes MellitusTerminatedNCT02093221Phase 2Results posted
• Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"CompletedNCT02001688Phase 2Results posted
• Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial InfarctionCompletedNCT01936896Phase 1/2Results posted
• A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host DiseaseCompletedNCT01700036Phase 2Results posted
• Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.CompletedNCT01669421Phase 2Results posted
• GLASSIA Infusion Rate StudyCompletedNCT01651351Phase 4Results posted
• Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant SuitabilityCompletedNCT01615484Not applicableResults posted
• Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin DeficiencyTerminatedNCT01379469Phase 2Results posted
• Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin DeficiencyCompletedNCT01213043Phase 2Results posted
• Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin DeficiencyCompletedNCT01054339Phase 2Results posted
• Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.CompletedNCT00670007Phase 4Results posted
• Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) DeficiencyCompletedNCT00430768Phase 1Results posted
• Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)CompletedNCT00396006Phase 4Results posted
• Aralast alpha1-proteinase Inhibitor Surveillance StudyTerminatedNCT00313144Phase 4Results posted
• The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) DeficiencyCompletedNCT00301366Phase 3Results posted
• Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient AdultsCompletedNCT00295061Phase 3Results posted
• Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor DeficiencyCompletedNCT00261833Phase 4Results posted
• Pharmacokinetic Study of ARALAST (Human Alpha1- PI)CompletedNCT00242385Phase 1Results posted
• NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung DiseaseWithdrawnNCT06622668Phase 1/2
• A Phase 1, First-in-human Study of VX-668CompletedNCT05727800Phase 1
• Maternal alpha1 Antitrypsin as a Marker of Intrauterine Growth Restriction in Pre-eclamptic WomenStatus unknownNCT05622838
• A Phase 1, First-in-human Study of VX-634CompletedNCT05579431Phase 1
• A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-EmphysemaWithdrawnNCT05466747Phase 4
• An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)WithdrawnNCT05146882Phase 2
• Functional and Structural Lung Imaging in Chronic Obstructive Pulmonary DiseaseStatus unknownNCT04966221
• Alpha-1-Antitrypsin-Deficiency in COVID-19CompletedNCT04799873
• A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ SubjectsTerminatedNCT04443192Phase 1
• ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) StudyWithdrawnNCT04440488Phase 4
• Respreeza® Self-administration and Learning Program (AmAREtTI Study)CompletedNCT04262284
• EARCO REGISTRY. History Of Patients With Alpha-1 AntitrypsinStatus unknownNCT04180319
• Study of DCR-A1AT in Healthy Adult VolunteersCompletedNCT04174118Phase 1
• COPD Exacerbation Blood and Urine Biomarkers StudyTerminatedNCT03823443
• Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin DeficiencyCompletedNCT03815396Phase 1
• Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency PatientsStatus unknownNCT03802357Not applicable
• A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver DiseaseTerminatedNCT03767829Phase 1/2
• A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.CompletedNCT03636347Phase 2
• Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin DeficiencyWithdrawnNCT03385395Phase 2
• The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin DegradationStatus unknownNCT03285100
• α1-antitrypsin (AAT) Levels and Functions in Allogeneic Bone Marrow Transplantation and Throughout Progression Into GVHDCompletedNCT03188601
• Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)No longer availableNCT03172455
• Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin DeficiencyCompletedNCT03114020Phase 2
• The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin DeficiencyCompletedNCT03039335
• Liver Disease in Patients With alpha1-antitrypsin DeficiencyStatus unknownNCT02929940
• FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)CompletedNCT02922751
• Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin DeficiencyCompletedNCT02691611
• Microbioma in Sputa From COPD With Alpha-1 Antitrypsin DeficiencyCompletedNCT02547532
• A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver DiseaseTerminatedNCT02503683Phase 1
• Environment Effect on Six-Minute Walk Test PerformanceTerminatedNCT02502201Not applicable
• Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin DeficiencyWithdrawnNCT02273349Not applicable
• Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac SurgeryStatus unknownNCT02191839Phase 1/2
• Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica RelapsesWithdrawnNCT02087813Phase 1
• AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient RegistryCompletedNCT01974830
• Genomic Research in Alpha-1 Antitrypsin DeficiencyCompletedNCT01832220
• Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)CompletedNCT01810458
• Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at HomeCompletedNCT01676688
• Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01419158
• Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patientsCompletedNCT01380626Not applicable
• Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin DeficiencyTerminatedNCT01357460Not applicable
• Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic FibrosisCompletedNCT01347190Phase 1
• The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 DiabetesCompletedNCT01319331Phase 1
• Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes MellitusCompletedNCT01304537Phase 1/2
• Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant SuitabilityTerminatedNCT01241942Not applicable
• International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With EmphysemaCompletedNCT01217671Phase 2/3
• Management of Patients With Alpha-1 Antitrypsin Deficiency Associated EmphysemaStatus unknownNCT00700934
• The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin DeficiencyCompletedNCT00532805
• Alpha-1 Foundation Research RegistryCompletedNCT00499941
• Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis PatientsCompletedNCT00499837Phase 2
• Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin DeficiencyCompletedNCT00460096Phase 2/3
• Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin DeficiencyCompletedNCT00377416Early Phase 1
• Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin DeficiencyCompletedNCT00161707Phase 1/2
• Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin DeficiencyCompletedNCT00157092Phase 1/2
• 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?CompletedNCT00067756Phase 2
• Alpha1-antitrypsin Deficiency RegistryCompletedNCT00005292
• Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin DeficiencyTerminatedNCT00005098
• Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient IndividualsCompletedNCT00001462

← Alpha 1-Antitrypsin Deficiency overview